IN WHAT the company considers a major milestone, the Phase I clinical trial of ASX-listed medicinal cannabis company Bod Australia's long-promised 'Cannabis Wafer Product' has been approved by the Therapeutic Goods Administration.
Recruited patients have now been identified and first visits for the trial commenced yesterday.
The Cannabis Wafer Product is a combination of a proprietary phytocomplex cannabis extract sourced from Swiss pharmaceutical company, Linnea which is suspended in iX Biopharma's patented sublingual wafer.
The product is to be tested in the future for specific indications including chemotherapy-associated nausea and vomiting, multiple sclerosis, epilepsy, anti-inflammation treatment and anxiety management.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jul 18
